Cytovance Biologics, Inc. has entered a development and manufacturing agreement with Selexys Pharmaceuticals for SELK2, an investigational humanized monoclonal antibody for the potential treatment of Crohn’s Disease and Multiple Myeloma. Cytovance will provide process development, scale up and cGMP manufacturing services of SELK2 to support a Phase I trial.
 
“With this agreement, Selexys continues its longstanding relationship with Cytovance,” said Dr. Scott Rollins, president and chief executive officer of Selexys. “Cytovance has been an integral part in helping us advance our clinical trial programs. We look forward to working with the company’s team of professionals on this new product for the treatment of inflammatory diseases and cancer.”
 
“Cytovance has been a manufacturing provider for Selexys since 2010 and welcomes this new project of SELK2 drug product for Phase I clinical materials,” said Darren Head, president and chief executive officer of Cytovance Biologics, Inc. “We are proud to be an established partner with Selexys and support them in finding an effective therapy for Crohn’s Disease that affects nearly 500,000 patients in the U.S.”